E-izglītība

Ace Therapeutics recently underscored its commitment to advancing chronic kidney disease (CKD) therapeutic development by offering one-stop CKD contract research services with a robust portfolio of validated CKD animal models. Designed to address the complexity of CKD pathophysiology, these offerings enable biotech and pharmaceutical clients to evaluate potential therapies with translational relevance, mitigating risks in downstream development.

Kidney disease occurs when the kidneys are damaged and lose their ability to effectively filter waste from the blood. CKD is a progressive condition encompassing a spectrum of renal dysfunctions, from early glomerular injury to late-stage fibrosis and end-organ failure. To reflect this heterogeneity, Ace Therapeutics has developed a diverse suite of CKD animal models that recapitulate key hallmarks of human disease—including fibrosis, inflammation, reduced glomerular filtration rate (GFR), and metabolic complications. The core CKD animal models include:

l  Unilateral Ureteral Obstruction (UUO) Fibrosis Model: Induced via flank incision ligation of the left ureter, validated through tubulointerstitial fibrosis assessment, collagen I/III immunostaining, and measurement of BUN, serum creatinine, and extracellular matrix (ECM) deposition.

l  Adenine Diet-Induced Injury Model: Utilizing 0.50-0.75% adenine in chow for 4 weeks, with validation endpoints including renal crystalline deposits, inflammation, tubular atrophy, and interstitial fibrosis.

l  5/6 Nephrectomy (Remnant Kidney) Progression Model: Generated by removing one kidney and inducing 2/3 infarction or pole ablation of the contralateral kidney, validated through progressive albuminuria, glomerulosclerosis scoring, and BUN/Cr monitoring.

l  Spontaneously Hypertensive Rat (SHR) Model: Leveraging genetic hypertension in bred lines, with key endpoints including arteriolar media hypertrophy, glomerulosclerosis, proteinuria, and blood pressure elevation.

Complementing its CKD animal models, Ace Therapeutics' CKD contract research services deliver end-to-end support across preclinical development. The company's multidisciplinary team—combining decades of nephrology expertise with cutting-edge methodologies—guides clients from study design to data delivery, integrating surgical, dietary, and chemical induction approaches as needed. All studies adhere to standardized protocols, power-based animal allocations, and blinded endpoint assessments, with rigorous QA/QC and traceability checks to ensure data quality and reproducibility.

The CKD contract research services also include access to state-of-the-art analytical capabilities to characterize disease progression and therapeutic responses. These include histopathological quantification (via PAS, Masson's trichrome, and collagen immunostaining), biomarker profiling (serum/urine creatinine, BUN, fibrotic mediators), non-invasive in vivo imaging (microCT, high-frequency ultrasound, MRI, PET, SPECT), and functional assays (albumin-to-creatinine ratio, blood pressure monitoring via tail-cuff or telemetry).

Ace Therapeutics further differentiates its offerings by providing customizable solutions—adapting induction methods, dosing regimens, and endpoint selections to align with clients' specific therapeutic targets and modes of action. The company's dedicated project managers and scientific liaisons ensure transparent communication throughout the study lifecycle, fostering long-term partnerships with clients focused on advancing renal care. For biotech and pharmaceutical companies seeking to navigate the complexities of CKD preclinical development, Ace Therapeutics' CKD contract research services and CKD animal models offer a trusted, comprehensive solution.

About Ace Therapeutics

Ace Therapeutics delivers specialized preclinical research services to support drug development across therapeutic areas. The company's validated models, state-of-the-art analytical capabilities, and collaborative approach enable clients to make informed decisions at every stage of preclinical research.